Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Alumis (NASDAQ:ALMS) through any online brokerage.
Other companies in Alumis’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Alumis has a consensus price target of $30.70.
The stock price for Alumis (NASDAQ: ALMS) is $6.855 last updated October 13, 2026 at 9:42 AM EDT.
There are no upcoming dividends for Alumis.
Alumis does not have any upcoming earnings scheduled.
There is no upcoming split for Alumis.
Alumis is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.